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Introduction
For over 40 years, Canada has had a publicly funded, national
health-care system designed to ensure residents receive “rea-
sonable access” to “medically necessary” health-care services,
regardless of their ability to pay [1]. However, unlike many of its
European counterparts, Canada’s system is a decentralized one,
comprised of 13 separate provincial and territorial health insur-
ance plans. Guided by common values (e.g., equity and solidar-
ity) and responsible for meeting basic standards of coverage,
these plans determine how best to organize, manage, and deliver
health care within their jurisdictions. Decisions regarding which
new technologies to include in the basket of publicly funded
services, therefore, rest with individual provinces and territories,
and the role of the federal government remains primarily limited
to premarket approval and, in the case of patented pharmaceu-
ticals, price regulation. It has, however, retained responsibility
for providing services to limited populations, such as veterans,
the military, ﬁrst nations, and inmates.
Canada’s history in health technology assessment (HTA), a
ﬁeld developed to support purchasing or coverage decisions,
reﬂects the decentralized nature of the country’s health-care
system. Its roots predominantly exist at the provincial level, with
the establishment of the Conseil d’evaluation des technologies de
la sante (CETS) (now called the Agence des technologies et des
modes intervention en sante [AETMIS]) in Quebec 20 years ago
[2]. At around the same time, a joint committee representing the
federal, provincial, and territorial ministries of health identiﬁed
HTA as one of its key priorities and announced the creation of
a national, independent HTA body called the Canadian Co-
ordinating Ofﬁce of Health Technology Assessment (renamed
the Canadian Agency for Drugs and Technologies in Health
(CADTH) in 2006). Funded by the provincial, territorial, and
federal governments, its mandate is to provide impartial,
evidence-based information on the clinical and economic impli-
cations of drugs and other health technologies (including devices,
procedures, and systems) to the 13 public insurance plans. Since
then, HTA has played an increasingly important role in technol-
ogy coverage policy in Canada. With the demand for assessments
exceeding resources available to the national HTA agency and
the types of requests broadening to include context speciﬁc ques-
tions framed from perspectives other than that of society, the past
20 years have seen the emergence of local HTA initiatives in
hospitals, regional health authorities, and provinces across the
country. Now more than ever, decision-makers at all levels of
government are investing in “institutionalized” HTA, creating a
landscape shaped by a combination of ongoing national and
local efforts.
In this article, the production and use of HTA in health-care
decisions in Canada is described in Section I. Current issues in
technology assessment are discussed in Section II. Section III
represents our personal views on lessons learned from the HTA
experience in Canada.
SECTION I: HTA AND ITS USE IN
HEALTH-CARE DECISIONS IN CANADA
Coverage decision-making processes vary not only by province
or territory, but also by type of technology (i.e., pharmaceutical
vs. nonpharmaceutical technologies), inﬂuencing the way in
which HTA is conducted and used.
National Efforts to Produce HTA
CADTH, Canada’s national HTA agency, remains the largest
producer of HTA in the country. Governed by a board represent-
ing the federal, provincial, and territorial ministries of health (not
including Quebec), CADTH carries out assessments on technolo-
gies deemed to be of national interest [3]. Speciﬁcally, potential
technologies (including devices, systems, and existing drugs) are
identiﬁed by the various levels of government and forwarded to
one of two CADTH committees, depending on their type:
the Advisory Committee on Pharmaceuticals or the Devices
and Systems Advisory Committee. These committees, whose
members also represent the federal, provincial, and territorial
ministries of health, review the requests and identify those that
should receive highest priority, from a national perspective, for
assessment. HTAs of the selected technologies are then carried
out in-house or commissioned to external public or private
research organizations. Therefore, only a handful of the devices,
systems, and existing drugs that comprise Canada’s health-care
system undergo formal reviews of their clinical and cost effec-
tiveness. This is not the case for new drugs (i.e., those recently
approved for sale in Canada but not yet reimbursed or covered
through one of the publicly funded drug beneﬁt plans). In Sep-
tember 2003, Canada launched the Common Drug Review
(CDR) process, through which all new drugs, except for anti-
cancer agents, must pass before a listing decision is made by the
federal, provincial (not including Quebec), or territorial drug
plans (CDR is a voluntary initiative for provincial and territorial
plans) [4]. Housed at and managed by a dedicated directorate
within CADTH, the CDR undertakes HTAs of new drugs for the
purposes of providing listing recommendations to all of the drug
plans. Accordingly, it represents an effort to reduce duplication
and maximize the consistency and quality of assessments being
used to aid such decision-making across the country [5]. The
CDR process broadly comprises three steps [6]. A submission
is prepared by the manufacturer in accordance with explicit
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submission guidelines and sent to the CDR Directorate. A
Review Team (consisting of in-house and contracted reviewers
and external experts) is assembled to draft a report based on
clinical and economic evidence provided by the manufacturer
and identiﬁed through independent literature searches. The
report is then reviewed by the Canadian Expert Drug Advisory
Committee (CEDAC) (a national, appointed body of physicians,
pharmacists, other health-care professionals, and a member of
the public), which evaluates the comparative therapeutic beneﬁts
and cost-effectiveness of the drug relative to accepted therapy
and makes one of three funding recommendations to participat-
ing plans: list without conditions (“yes”), list with conditions, or
do not list (“no”). Lastly, the recommendation is considered
separately by each plan, which independently makes its own ﬁnal
decision. The CDR reviews drug submissions on a ﬁrst-come-
ﬁrst-served basis, and manufacturers, as well as physicians
seeking coverage for a new drug through one of the participating
drug plans can initiate the process. However, exceptions may be
made for drugs that meet criteria for priority review (new drug
for an immediately life-threatening condition or serious disease
for which there is no comparable available drug or new drug that
could signiﬁcantly (i.e., $2.5 million Cdn/year) reduce drug
expenditures. Since its inception, the CDR has reviewed approxi-
mately 120 new drugs.
Local Efforts to Produce HTA
The ministries of health in three of Canada’s 13 provinces and
territories have created and invested considerably in HTA initia-
tives designed to meet their speciﬁc needs. AETMIS, the HTA
unit at the Institute of Health Economics (previously housed
within the Alberta Heritage Foundation for Medical Research
[AHFMR]) and the Medical Advisory Secretariat within On-
tario’s Department of Health and Long-Term Care comprise
government-funded HTA bodies whose sole role is to produce
assessments for policymakers in Quebec, Alberta, and Ontario,
respectively. In both Alberta and Ontario, their work is supple-
mented by that of university-based programs, which hold grants
from the ministries of health to not only conduct HTAs but also
build HTA capacity in the two provinces [7,8]. On an even more
local level, some hospitals in Quebec and regional health authori-
ties in Alberta have established their own HTA units to generate
information needed for speciﬁc technology acquisition and man-
agement decisions [9].
Although the scope, structure, format, and components of the
reports vary with the requesting body (e.g., government, RHA,
hospital, etc), approaches to ensuring their quality do not.
Canada’s HTA community has long been engaged in developing
and implementing mechanisms for preparing rigorous, scientiﬁ-
cally credible HTAs, producing one of the ﬁrst sets of critical
appraisal criteria and economic evaluation guidelines [10–12].
Adherence to these or similar guidelines is, if not mandatory,
expected by those requesting and undertaking HTA across the
country, regardless of the type of technology. In addition, each
HTA organization has an established review process, overseen by
a governing or advisory board, that incorporates input from
clinical and methodology experts who are appointed on a per
project basis. Lastly, reports are typically submitted for publica-
tion, in one form or another, to relevant peer-reviewed journals,
with acceptance serving as a measure of their international
credibility.
National use of HTA. Approximately 5 years ago, a comprehen-
sive, pan-Canadian strategy for HTA, “which assesses the impact
of new technology and provides advice on how to maximize its
effective utilization in the future,” was commissioned and
approved by the Conference of Federal/Provincial/Territorial
Deputy Ministers of Health [13]. Shortly thereafter, ﬁnancial
contributions to CADTH by the federal government increased
exponentially. Although it may be argued that such a funding
commitment is, in itself, an indication of the value of HTA to
policymakers across the country, there have been relatively few
formal attempts to examine, on a national level, exactly how it is
used in decision-making [14].
Local use of HTA. Evidence of the use of HTA by local decision-
makers is similar in quality and quantity to that reported nation-
ally. Government investment in the three provincial HTA
programs, informed by evaluations of their effectiveness from the
funder’s perspective, continues to increase at a time when there is
heightened public accountability and scrutiny over expenditures
on all health-care services and programs. Although such evalua-
tions appropriately address questions of whether or not HTA is
used, they generally provide little insight into the way in which
it is used [15,16]. Recognizing this, Alberta’s HTA unit, then
located at AHFMR, developed a conceptual framework for
assessing the impact of HTA. Although not yet implemented, this
framework takes into account the various roles that HTA can
play in decision-making, and encourages those involved to give
careful consideration to the role that HTA has played in such
processes [17].
The scarcity of information describing the use of HTA in
Canada, both on a local and national level, may simply be a
reﬂection of the environment in which it is employed. Over the
years, several published studies and commissioned reports have
highlighted the lack of clarity around how evidence, in general,
informs funding decisions, calling for greater transparency in
such processes [14,18,19].
SECTION II: CURRENT ISSUES IN
TECHNOLOGY ASSESSMENT
Not surprisingly, current issues in Canadian HTA fall into one of
two categories, those related to the production of HTA (i.e.,
assessment of technologies) and those related to its use.
Issues Related to the Production of HTA
Prioritizing technologies for assessment. Determining which
technologies to assess and in what order continues to be a chal-
lenge for most HTA organizations in Canada. Although this
challenge has been minimized for new pharmaceuticals with the
creation of the CDR, there is still a need to set priorities when
“priority reviews” emerge and disrupt the “ﬁrst-come-ﬁrst-
served” system. As indicated earlier, the CDR has published
criteria for deﬁning priority pharmaceuticals and balancing their
review along side those already underway. However, public infor-
mation on the application of these criteria in practice is scarce.
The same can be said for technologies that are not part of the
CDR (i.e., existing and nonpharmaceuticals). Despite the avail-
ability of criteria developed by CADTH for selecting existing
drugs, devices, and systems for assessment (the content of which
is similar to those of other HTA organizations around the world),
little is known about how these criteria are actually used to guide
decisions (e.g., is one criterion weighed more heavily than
another?) [20]. In the recent years, it has become increasingly
clearer that priority-setting for HTA is value-laden, igniting calls
for input from stakeholders beyond that of the funder [21].
Initial efforts to achieve this have focused on the public, with the
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conduct of a citizen’s jury aimed at identifying criteria the public
feels should be used to set priorities for HTA [22]. Last year, the
Ontario legislature passed a bill mandating the creation of a
Citizens’ Council to advise government on the social aspects of
pharmaceutical policies and priorities, and commissioned the
Institute for Clinical Evaluative Studies to prepare a report pre-
senting recommendations for implementing it [23]. Since then,
the report has been released, but a decision by government on
how best to proceed has yet to be announced.
The remaining issues pertain to the types of evidence/data
often available for assessment. Canada’s HTA community has
traditionally played an active role in both the development of
methodologies for producing comprehensive, scientiﬁcally cred-
ible HTAs and the establishment of evidence expectations for
arriving at decisive recommendations [10]. However, the extent
to which these methodologies can be applied and expectations
met depend, in part, upon the availability and nature of existing
data. In HTA, such data largely consist of international clinical
studies and economic analyses. Thus, it is reasonable to expect
that the issues described in the further discussion are shared by
most HTA producers around the world.
Relative therapeutic value versus relative efﬁcacy. For pharma-
ceuticals, data are frequently limited to that required for market
approval by Health Canada (i.e., evidence of safety and efﬁcacy).
As a result, they typically comprise placebo-controlled random-
ized trials of efﬁcacy, rather than effectiveness, with relatively
short follow-up periods. In the absence of the effectiveness data,
HTA producers resort to using modeling techniques and sensi-
tivity analyses to examine parameters such as longer time frames
and possible variations in efﬁcacy. However, even the most
rigorous models often fall short of capturing not only important
aspects of a drug when introduced into the “real world” (e.g.,
therapeutic beneﬁt in the presence of comorbidities, adverse
effects caused by polypharmacy, etc.), but also outcomes of value
to patients, payers, and the broader public, as trials conducted
for regulatory purposes typically focus on narrower, clinical mea-
sures (e.g., change in blood pressure or length of survival). In
Canada, there is a growing body of literature suggesting that
quality of life is one of citizens’ top priorities [18,21,22]. There-
fore, recognizing uncertainties in the relevance and validity of
models, HTA review committees charged with developing rec-
ommendations are reluctant to place much weight on their
results (Manns B. Chair, CEDAC. Personal communication,
2007) [24]. Given the absence of similar regulatory requirements
for nonpharmaceutical technologies, available data are much less
predictable, usually comprising studies of weaker design and
quality [25]. Consequently, decisions around which of them to
include in an HTA become judgment calls, which can lead to
different ﬁndings across assessments of the same technology
[26,27].
Incorporating values-based data. In Canada, national efforts to
more meaningfully describe the value of a technology through
HTA have focused on the ways of capturing the perspectives of
patients and payers [3]. For patients, HTA relies on values-based
data from studies measuring health-related quality of life
(HRQOL). This information is then input into cost-utility analy-
ses, which offer a means of establishing the value of a technology
as seen by the payer. However, for some technologies, HRQOL
data are not available, precluding the assessment of their value
from the patient’s perspective. Within the past couple of years,
HTA has faced pressures to also examine the value of technolo-
gies to the public, and some preliminary work has been done
[28]. A conceptual framework for accomplishing this has been
developed but not yet implemented [21].
Transferability of economic information. Findings from a scan
of HTA reports recently released by CADTH indicated that,
where economic evaluations were performed, Canadian costing
information—primarily from administrative databases—was
used. However, all of the technologies assessed had already been
introduced into the health-care system. In the case of new tech-
nologies for which no Canadian data are available, costs are
generally extracted from sources that most closely reﬂect the
Canadian context (i.e., public health-care system in a westernized
country) and then converted into Canadian dollars. In compli-
ance with CADTH’s economic evaluation guidelines, sensitivity
analyses are carried out around estimates to account for any
uncertainties in them [12]. To the extent possible, costs for stan-
dard or common items associated with the use of a technology
(e.g., operating room time, overnight hospital stay, nursing time,
diagnostic tests, physician visits, etc.) are taken from local fee or
reimbursement schedules, limiting the number of estimates
required to a few technology-speciﬁc items [8].
Generating and using real-world data. Traditionally, HTA in
Canada has comprised a form of secondary research, relying on
existing data from various kinds of scientiﬁc studies. However,
heightened awareness of the lack of sufﬁcient evidence regarding
the effectiveness of many new nondrug-related technologies has
resulted in a commitment by the federal government to establish
a coordinated Field Evaluation system [13]. As described in
Canada’s national strategy for HTA, ﬁeld evaluations are mecha-
nisms for obtaining evidence to support decision-making through
primary research on the effectiveness of promising new technolo-
gies for which no “real-world” data exist, while meeting the care
needs of patients who may beneﬁt. On a local level, the Ontario
Ministry of Health and Long-Term Care has already launched it
own ﬁeld evaluation program, partnering with clinical and aca-
demic research institutions around the province [29]. Although
10 such projects have been completed, and 24 are currently
underway, no public information on the methodologies being
applied appears to be readily available.
Field evaluations may also offer a means of dealing with
issues of information scarcity surrounding certain high-cost
drugs, such as those for orphan diseases. Enzyme replacement
therapies used to treat Fabry disease and mucopolysaccharidosis,
two extremely rare, inherited metabolic disorders, received nega-
tive recommendations from CEDAC on the grounds of insufﬁ-
cient evidence [30,31] This raised questions as to whether or not
it would ever be feasible to collect enough information to satisfy
a CDR-type organization when the condition affects only
1/100,000 individuals. Such questions remain unanswered.
Importantly, the ﬁeld evaluation concept is akin to that of
Coverage with Evidence Development, which was recently intro-
duced into the United States Medicare and Medicaid Services
reimbursement system [32].
Timeliness. HTA producers in Canada and abroad continue to
face criticism over the turnaround times for assessments, which
have often been well over a year. Nationally, CADTH has
responded by creating a Health Technology Information Service,
designed to provide information to decision-makers based on the
“best available evidence” within 1 to 30 business days, depend-
ing on the urgency of the request. Responses range from “a list of
the best evidence-based information to a formal report that
includes an appraisal of the ﬁndings” [33]. Locally, both Ontario
and Alberta have created systems through which full HTA
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reports are to be completed within 2 and 3 month timeframes,
respectively (from topic assignment to submission of the report)
[7,8]. However, the extent to which this has actually been
achieved remains unclear.
Lastly, to further address some of the issues discussed earlier,
Canada’s national HTA strategy called for the creation of a
network of HTA producers across the country who would share
knowledge, information, and experiences related to the collec-
tion of evidence and policy advice [15]. Such a network was
established by CADTH approximately 2 years ago and is called
the Health Technology Analysis Exchange (Exchange) [34].
Explicit details regarding its upcoming activities or priority
topics have not yet been released.
Issues Related to the Use of HTA
HTA and innovation. Historically, HTA has been viewed by
many as a “gatekeeper” for the health-care system. Technologies
are often selected for assessment because of concerns over their
potential ﬁnancial impact [20]. As a result, HTA is seen as a way
to say “no” to such technologies. However, in recent years, HTA
has also become recognized as an enabler for the introduction of
promising new technologies. Canada’s Health Technology Strat-
egy includes both innovation and HTA in its description of the
life cycle of technologies and proposes a role for HTA in the
development of new products [15]. Such plans to create a system
through which HTA feeds into innovation and encourages it have
not yet been implemented.
Transparency in decision-making. As discussed earlier, little is
available in peer-reviewed literature about how HTA is actually
used in decision-making across Canada. In fact, little is known
about decision-making processes, both at the national and local
levels. The lack of transparency has become particularly frustrat-
ing for patients and manufacturers searching for answers to why
certain technologies received negative recommendations or deci-
sions [14]. The CDR is taking steps to “open up” its process
through the appointment of members of the public to CEDAC.
Independence. In Canada, technology coverage decisions are
primarily made at the provincial or territorial level. This has
created inequities in access to certain technologies across the
country [35–37]. However, whether variations in the use of HTA
by different decision-making bodies have contributed to such
inequities is difﬁcult to assess, given the lack of transparency
around their processes.
One recently implemented initiative that may help to provide
insight into such issues is the Health Technology Policy Sharing
Forum (Forum) established by CADTH [38]. First proposed in
Canada’s HTA strategy, it is intended to serve as a mechanism for
bringing together decision-makers across the country to discuss
common areas of interest related to health technology policy
[15].
Health policy and politics. Studies examining resource alloca-
tion and priority setting processes in different jurisdictions across
the country have revealed that evidence is only one of the many
factors that inﬂuence decisions [19]. Although phrases such as
“an efﬁcient health-care system” and “equitable access to ser-
vices” are often associated with Canadian health policy state-
ments, there are neither real mechanisms in place nor common,
agreed-to deﬁnitions to help ensure that either endeavor is
achieved. Findings from surveys of decision-makers have indi-
cated that, on occasion, evidence has been “trumped” by politi-
cal imperatives [39].
Silo budgeting. Health economists have long demanded that eco-
nomic evaluations of health-care services be conducted from the
societal perspective. In fact, most “best practice” guidelines for
the production of such evaluations have made this an explicit
requirement [12]. The difﬁculty is that no single “societal”
budget exists. Decisions are typically made by budget holders
who have responsibility for and authority over a small slice of the
health-care pie (e.g., a provincial government drug coverage
program, physicians’ services, home care, diagnostic services,
etc.). Therefore, what might be cost saving for one of these
budgets might be cost-increasing for another. As a result, tech-
nologies shown to be cost-effective through evaluations con-
ducted from the societal perspective are deemed inefﬁcient
because of budget structures. Currently, economic analyses
included in HTAs produced on a local level are, more often than
not, taking on the funder’s or payer’s perspective [7,8].
Parallel trade. Because of price differences for pharmaceuticals
between Canada and the United States, parallel trade for these
products exists. Although the magnitude (in terms of number of
prescriptions and expenditures) represents only a small fraction
of total pharmaceutical expenditures in the United States, it is
signiﬁcant enough to have drawn considerable media attention in
recent years. There are a number of reasons for this, including
price regulation at the Canadian federal level and the role of
individual provincial formularies in setting price (which essen-
tially becomes the standard price for a product for all buyers)
[40]. HTA is an inﬂuence insofar as its role in formulary listing
decisions are concerned. Although the CDR, based on HTA,
offers listing recommendations that a provincial pharmaceutical
program might decide to adopt, the process, in itself, is not a
factor in price determination.
Patient and provider choice. For pharmaceuticals, there are three
groups of payers in Canada: 1) the federal, provincial, and terri-
torial governments (through social assistance, seniors, and other
specialized programs, and universal coverage plans inQuebec and
Saskatchewan), 2) insurance companies (providing coverage to
some individuals and employees of organizations and businesses),
and 3) individuals who do not fall into at least one of the ﬁrst two
categories. In the ﬁrst two groups, patient choice is limited to
pharmaceuticals included in formularies or beneﬁt lists, the con-
tents of which are determined by government or the insurance
company. Because HTA—through the CDR—is part of all
government-based decision-making processes, it has the potential
to inﬂuence patient access. Insurance companies typically base
their coverage decisions on those already made by government.
However, physicians may prescribe any product that has received
market approval from the federal government. Several years ago,
the province of British Columbia implemented reference-based
pricing for certain classes of pharmaceuticals. Therefore, if either
a provider or patient chooses any product other than the reference
product, the patient is responsible for paying the difference out-
of-pocket [41]. For nonpharmaceutical technologies, the govern-
ment is the primary payer. As with pharmaceuticals, governments,
through their decision-making processes, determine which new
technologies to provide. In provinces where HTA is also a part of
such processes, it has been used as a way of ensuring that infor-
mation on patient preference is considered [8].
Effects on budgets, reimbursement and coverage. As discussed
earlier, HTA comprises only one of many factors considered by
those involved in making funding decision across Canada, and its
weight relative to these other factors remains unclear, even in
general terms.
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Quality-adjusted life year (QALY) thresholds. A cost/QALY
threshold was ﬁrst suggested in 1992 in Canada [42]. The pro-
posed ﬁgure was $20,000 per QALY (1992 dollars) for the
threshold below which a new technology ought to be adopted,
and $100,000 per QALY for the threshold above which a new
technology should not be adopted. A threshold ﬁgure that is cited
now is US $50,000 per QALY. However, there is no formal
evidence that any of these boundaries has ever been accepted or
implemented by any Canadian decision-making body [36]. In
fact, Laupacis has since stated that the traditional $50K/QALY
“would be considered relatively unattractive” [43]. There has
also been debate about the relevance of a threshold, and of the
ICER itself, in resource allocation decision-making [44]. Thus,
although QALY thresholds might exist in an implicit sense,
there is no explicit evidence that they have been used during
decision-making.
SECTION III: LESSONS FOR OTHER
JURISDICTIONS
Health-care systems of the countries included in this Special Issue
are, in many ways, very different from Canada’s publicly funded,
decentralized one. Nevertheless, some of the key challenges that
Canada has faced are system-independent.
It is difﬁcult, if not impossible, for a single HTA body to meet
the information needs of decision-makers unless it is operating
within a single payer system, such as the United Kingdom. In
Canada, HTA has evolved to include a combination of national
and local initiatives, reﬂecting the decentralized nature of its
health-care system. Local initiatives, comprising HTA programs
in several provinces, regional health authorities, and hospitals,
provide “tailor-made” assessments framed in a local context.
Because they maintain close linkages with the policymaking
environment, they are well positioned to be able to respond to
HTA requests in accordance with time frames established by
decision-makers.
This distributed HTA activity has two consequences. As the
decision-making focus moves from the national to a local level,
the speciﬁc information needs become somewhat different.
Although a “one-size-ﬁts-all” approach to HTA may be appro-
priate for certain technologies, information and data speciﬁc to
local environments (e.g., patient preference, resource implica-
tions, ethical considerations, implementation issues, etc.) is
playing an increasingly important role in decision-making. As
well, the methodological challenges become different, as, for
example, the kinds of data available at a local level might be
quite different from a national or state level. Methodological
guidelines do exist for HTA, but they generally employ a societal
perspective. Typically, health-care authorities take a payer’s
perspective.
Timeliness continues to be an issue with HTA in Canada. For
example, out of necessity, CADTH has had to establish increas-
ingly bureaucratic processes for HTA, and, as a result, these
processes become lengthier. At the provincial level, attempts are
being made in Alberta and Ontario to speed up the production of
HTA reports; but it is not clear, at least at this point, what effect
they have had on decision-making.
Transparency of HTA, as well as decision-making informed
by HTA, continues to be criticized. For example, the exact role
that cost-effectiveness analyses play in decisions of the CDR is
not explicit. This is not unique to Canada, as HTA bodies in
other countries have faced similar criticisms. Ultimately, though,
this might be more of a criticism of decision-making in a complex
area such as health care, rather than of the ﬁeld of HTA itself.
HTA has had a long history in Canada, and governments
continue to invest in HTA programs. This would seem to suggest
that HTA is of use to these governments. But what has HTA
actually accomplished in Canada? There have been external
reviews of many of the HTA programs in the country, most of
which have been positive, and in some cases, have resulted in
additional funding. But important questions like what HTA has
done to improve the introduction and management of new tech-
nologies in health, what patient and population outcomes it has
helped achieve, how it has enhanced the introduction of prom-
ising new technologies, and what it has contributed to disinvest-
ment of obsolete or ineffective technologies remain, to a large
extent, unanswered.
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